Current management of DCIS: a review |
| |
Authors: | Neill Patani Bruno Cutuli Kefah Mokbel |
| |
Institution: | The London Breast Institute, The Princess Grace Hospital, 45 Nottingham Place, London, W1U 5NY, UK. neillpatani@hotmail.com |
| |
Abstract: | Ductal carcinoma in-situ (DCIS) is a heterogeneous disease, in terms of its radiological characteristics, histological morphology and molecular attributes. This diversity is reflected in its natural history and influences optimal treatment strategy. A significant proportion of DCIS lesions behave in a clinically benign fashion and do not progress to invasive disease. Reliable identification of these patients could allow treatment to be less radical or safely omitted. Management should be tailored to the individual within the context of a multidisciplinary team. Approaches such as biological profiling and molecular analysis represent an opportunity to improve our understanding of the tumour biology of this condition and rationalise its treatment. This article reviews the management strategies for DCIS in the context of recent randomized trials, including the role of sentinel lymph node biopsy, adjuvant radiotherapy and tamoxifen. |
| |
Keywords: | Ductal carcinoma in-situ Local recurrence Lumpectomy Management Margins Mastectomy Radiotherapy Sentinel lymph node biopsy Tamoxifen |
本文献已被 PubMed SpringerLink 等数据库收录! |
|